15th Annual Meeting & Gala
National Alliance of State Prostate Cancer Coalitions

“Participate, Educate, Celebrate”

October 18 - 20, 2019
Hotel Monaco, Washington, D.C.
The National Alliance of State Prostate Cancer Coalitions - “THE PROSTATE CANCER ALLIANCE” - welcomes you to our landmark 15th anniversary Annual Meeting & Gala! We are thrilled that each of you is able to attend this Meeting whose theme is “Participate, Educate, Celebrate” and hope that everyone will return to their respective states, groups and constituencies and spread the word about everything you learn here this weekend and share all the amazing developments taking place in Prostate Cancer.

Yesterday we held our Q4 Board of Directors Meeting at which the Board adopted a FY2019-20 Budget proposed to them by the Executive Committee to carry us forward in the coming year; this will enable us to work towards achieving exciting elements of our Strategic Plan. Today we will have Sessions beginning at 9:00 am at the conclusion of breakfast, that will continue until 5:00 p.m., including a morning and afternoon break and, of course, lunch. Topics include Prostate Cancer Genetics; Immuno-therapeutics; Clinical Trials; Androgen Deprivation Therapy; Prostate Cancer and African-American Men; Active Surveillance; Advanced Prostate Cancer; Recurrence; and Nutrition and Lifestyle.

Then we will re-convene at the Gala this evening beginning at 6:30 pm – a very exciting 15th Anniversary celebration that will honor our beloved Dr. Paul Schellhammer! The Gala will also see the presentation of the first ever James West Spirit Award that will be given to Phillip Buck Olsen, spirited prostate cancer warrior from Hawaii. Jim West was a Board Member for the 2018-2019 term but he passed away August 7, 2019. Last year Jim was the recipient of NASPCC’s “Most Spirited Advocate Award”, and he was always a tireless champion for early detection of prostate cancer with The Jim West Prostate Cancer Foundation in Florida. NASPCC has created the James West Spirit Award in his honor. The Prostate Cancer Alliance will also honor “The Most Outstanding State Prostate Cancer Organization” tonight.

Sunday we will start with breakfast at 8:00 and sessions (including lunch) will continue until 3:00 p.m. Topics include How to Approach Decision-Making; Optimizing Care in the Community; Managing the Side Effects of Prostate Cancer Treatment (including Intimacy, ED and Incontinence); and State Coalitions’ Best Practices. An Open Discussion from the Floor will conclude the Meeting.

Welcome!

Merel Grey Nissenberg,
President, “The Prostate Cancer Alliance” (NASPCC)
15th ANNUAL MEETING
NATIONAL ALLIANCE OF
STATE PROSTATE CANCER COALITIONS
“PARTICIPATE, EDUCATE, CELEBRATE”
SATURDAY, OCTOBER 19
AGENDA

<table>
<thead>
<tr>
<th>SESSION NAME</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breakfast</td>
<td>8:00 – 8:45</td>
</tr>
<tr>
<td><strong>I. THE BASICS</strong></td>
<td></td>
</tr>
<tr>
<td>1. Introduction and Welcome</td>
<td>9:00-9:10</td>
</tr>
<tr>
<td>2. Prostate Cancer 101: The basics you need to know.</td>
<td>9:10-9:35</td>
</tr>
<tr>
<td>3. Prostate Cancer Genetics 101</td>
<td>9:35-10:00</td>
</tr>
<tr>
<td>4. Basics of Prostate Cancer Immunology and Immuno Therapeutics</td>
<td>10:00-10:20</td>
</tr>
<tr>
<td>5. Demystifying Clinical Trials: What are they, and what should you think about when considering a trial?</td>
<td>10:20-10:40</td>
</tr>
<tr>
<td><strong>MORNING BREAK</strong></td>
<td>10:40-10:55</td>
</tr>
<tr>
<td>6. The ABCs of Androgen Deprivation Therapy</td>
<td>10:55-11:15</td>
</tr>
<tr>
<td>7. Prostate Cancer and African-American Men</td>
<td>11:15-11:35</td>
</tr>
</tbody>
</table>
II. TREATMENT OF NON-METASTATIC DISEASE BASED ON RISK ASSESSMENT:

8. Disease Location and Risk Assessment: 11:35-12:05  
   The scientific tools available to help  
   *Vincent Laudone, MD,

LUNCH "Meet the Experts"  12:05-1:05

9. "The Dawn of a New Era for Prostate Cancer Patients: The Role of PSMA and Artificial Intelligence in Diagnostics and Therapy"  1:10-1:25  
   *Asha Das, MD, FAAN  
   Chief Medical Officer, Progenics

10. Low Risk Localized PCa: Genomic Tests, Focal Treatment and Active Surveillance  1:25-2:05  
    *Vincent Laudone, MD  
    *Judd Moul, MD  
    *Daniel Song, MD, Johns Hopkins Medicine  
    *Gregory Gagnon, MD  
    Frederick Regional Health System, Maryland

11. Intermediate and High-risk Disease and Multimodal therapy  2:05-2:45  
    *Vincent Laudone, MD  
    *Paul Schellhammer, MD  
    FACS, Urology of Virginia, Norfolk, Virginia  
    *William “Jeff” Skinner, MD, Walter Reed Military Hospital

12. “Review of the ARAMIS Data presented at ASCO“  2:45-3:05  
    *Joseph Germino, MD, Bayer Pharmaceuticals

III. A SYSTEMATIC APPROACH TO SYSTEMIC THERAPY:

13. The optimal treatment of bone metastases  3:05-3:20  
    *Philip Saylor, MD, Harvard, Mass General

    *Mark Markowski, MD,PhD  
    Johns Hopkins University  
    *Paul Schellhammer, MD

AFTERNOON BREAK  3:55-4:05

15. Biochemical/PSA Recurrence of Prostate Cancer  4:05-4:35  
    *Judd Moul, MD

16. The Role of Nutrition and Lifestyle in addressing Prostate Cancer  4:35-4:55  
    *Joseph Scherger, MD,MPH  
    Eisenhower Medical Center

ADJOURN *****

GALA starts at  6:30 P.M.  
Paris Room, Hotel Monaco
# SUNDAY, OCTOBER 20

## AGENDA

<table>
<thead>
<tr>
<th>SESSION NAME</th>
<th>TIME</th>
<th>SPEAKERS/LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breakfast</td>
<td>8:00-8:45</td>
<td>Mark Vieth, CRD Associates</td>
</tr>
<tr>
<td>Current Update on the CDMRP and DOD Research Fund</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV. OPTIMIZING NASPCC: HOW CAN WE HELP STATES AND PATIENTS?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Report from the Steering Committee:</td>
<td>9:30-9:50</td>
<td>*Tom Kirk, and All Committee Reports from the Chairs</td>
</tr>
<tr>
<td>ELECTIONS for 2019-2020 Officers and Board</td>
<td>10:00-10:30</td>
<td>Jan Marfyak, Secretary</td>
</tr>
<tr>
<td>BREAK</td>
<td>10:30-10:40</td>
<td></td>
</tr>
<tr>
<td>V. FROM THE PATIENT’S PERSPECTIVE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical and Patient Perspectives</td>
<td></td>
<td>*Michael Zaragoza, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Gabe Rosko</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Dave Hulbert</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Phil Olsen</td>
</tr>
<tr>
<td>20. Optimizing Care in the Community Setting</td>
<td>11:25-11:55</td>
<td>*Ashley Ross, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Paul Schellhammer, MD, FACS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Gregory Gagnon, MD</td>
</tr>
<tr>
<td>LUNCH</td>
<td>12:00-1:00</td>
<td></td>
</tr>
<tr>
<td>21. Managing the Side Effects of Prostate Cancer and its Treatment: Emotional Distress, Intimacy Issues, Erectile Dysfunction and Incontinence</td>
<td>1:00-1:45</td>
<td>*Bill Goeren, MSW, OSW-C, LCSW-R, CancerCare</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Krishnan Venkatesan, MD, Washington Hospital Center</td>
</tr>
<tr>
<td>22. Attendees’ Round Table: Discussion And Questions from the Floor</td>
<td>1:45-2:15</td>
<td>All</td>
</tr>
<tr>
<td>23. Wrap Up; Calendaring and Conclusions</td>
<td>2:15-3:00</td>
<td>Merel Nissenberg</td>
</tr>
</tbody>
</table>

ADJOURN 3:00 p.m.
The National Alliance of State Prostate Cancer Coalitions (NASPCC) is a 501(c)(3) not-for-profit organization with an extensive network and national outreach through many state prostate cancer organizations and individuals. We are an Alliance comprised of many entities, including state prostate cancer coalitions, foundations, associations, and others who are interested in helping to save the lives of men with prostate cancer.

NASPCC – “The Prostate Cancer Alliance” – was formed in October 2004 to serve as an umbrella organization in which state prostate cancer organizations could participate and help generate “strength in numbers.” We have become a large critical mass and voice for prostate cancer patients and their families.

We advocate for Informed Decision-Making in prostate cancer, and we disseminate a durable, laminated awareness and education tool for patients AND for primary care providers. See www.prostatecaif.org/patient-guide. We hold an Annual Meeting to enhance education and to share best practices with patients across the country. The resources we disseminate make their way through to the states and reach down through to the local levels, including support groups and individuals who do not participate in those groups.

We actively provide, through our participating organizations: support groups, educational forums, webinars, workshops, prostate cancer information, and awareness and educational activities. We maintain a website www.naspcc.org and an active Facebook Page “National Alliance of State Prostate Cancer Coalitions.”

We advocate for the highest quality of life for prostate cancer patients and their families.

We have an Advisory Board comprised of influential and respected physicians, scientists and researchers.

We are many states strong and growing. We are “The Prostate Cancer Alliance”!

---

EDUCATIONAL OBJECTIVE

At the conclusion of NASPCC’s 15th Annual Meeting & Gala, attendees should be aware of the basics of prostate cancer; fundamentals of testing (genetic, genomic and other tests and imaging) and risk assessment; fundamentals of treatment for different stages of prostate cancer, including clinical trials; issues such as prostate cancer and African-American men; fundamentals of active surveillance; fundamentals of immunotherapy; fundamentals of biochemical/PSA recurrence; the importance of a healthy lifestyle in addressing prostate cancer; how to manage side effects from diagnosis and treatment; and how to ensure that patients have appropriate access to optimal care, whether they are treated at an academic center or in a community setting. This information should then enable patients – and those that help them make treatment choices – to make informed, individualized decisions with their physicians.
Merel Nissenberg, Esq. (California)  
President, National Alliance of State Prostate Cancer Coalitions  
Merel Grey Nissenberg, Esq. is a medical malpractice attorney in Los Angeles handling cases around the country, and she is President of three non-profits in healthcare: the National Alliance of State Prostate Cancer Coalitions (NASPCC); the California Prostate Cancer Coalition (CPCC), both of which she co-founded; and the Clifton F. Mountain Foundation for Education & Research in Lung Cancer. She is a member of two National Cancer Institute SPORES (one in Prostate Cancer at UCLA, one in Lung Cancer at M. D. Anderson Cancer Center), and she is on the UCLA SPORE Executive Committee. She is also the Advocate for the Canary Foundation/PASS Trial at Stanford (Prostate Active Surveillance) and is part of a PCORI Grant with UCLA dealing with decision aids in prostate cancer. Additionally, through her consulting group Informed Health Consulting she and her partner help accrue patients to Clinical Trials and also create Patient Ambassador Programs and Roundtables. Merel has been actively involved for almost ten years as one of three national Patient Advocates for the Early Detection Research Network (EDRN) of the National Cancer Institute, handling three of the four Collaborative Groups: GU Cancers, GYN Cancers, and Lung Cancer. In her law practice she has represented many cancer patients and has advocated for them and for their families. Merel is extremely interested in the early detection of cancers when they are still curable and is dedicated to improving the lives of patients, including those as-yet-undiagnosed.

Johnny Payne (South Carolina)  
Vice President, National Alliance of State Prostate Cancer Coalitions  
Johnny Payne is the Vice President of NASPCC. Johnny obtained his Bachelor’s Degree in Business Administration from Western Kentucky. Johnny is currently the Support Group Leader and Community Educator for the Greenville, South Carolina chapter of Us TOO International. Johnny is also a delegate to the ZERO Summit to End Prostate Cancer, Co-Chair of the South Carolina Alliance Prostate Cancer WorkGroup, and a Consumer Reviewer for the Congressionally-Directed Medical Research Program (CDMRP) for the DOD’s Prostate Cancer Research Program (PCRP).

Jan Marfyak (New Mexico)  
Secretary, National Alliance of State Prostate Cancer Coalitions  
Jan Marfyak is one of the founders of NASPCC, served as its Treasurer, and is currently Secretary. He has been on the Board of Directors since 2004, the year of its organization. Jan served in Wisconsin State government after leaving the University of Wisconsin, and later moved to Washington DC, first at the Department of Justice and later at the Department of Energy. He is a prostate cancer survivor (1975) and is Secretary of the Prostate Cancer Support Association of New Mexico, an active state prostate cancer organization.

Following treatment, Jan volunteered at the Foundation for Urological Disease in Baltimore, MD and later started the Pennsylvania State Prostate Coalition. Jan has been instrumental in helping to start other state prostate cancer organizations and in sharing his knowledge of budget and advocacy issues.

Donald Lynam, PhD (Kentucky)  
Treasurer, National Alliance of State Prostate Cancer Coalitions  
Don has been active in the prostate cancer community for approximately 20 years, with NASPCC, and before that, Us TOO. He has served on the Board of Directors (BOD), Executive Committee, and Treasurer of NASPCC for the past 9 years. Don is Vice Chairman of KY PCC. He is a past member and Vice Chairman of the BOD of Us TOO, and Chapter Leader of Us TOO of the Bluegrass (Lexington, KY) for the past 15 years.

Don has degrees in Engineering (B.S. and M.S.) from the University of Kentucky and Environmental Health (M.S. and Ph.D.) from the University of Cincinnati. He served 3 years in the US Air Force, as a commissioned officer, primarily at the US Air Force Flight Test Center and Rocket Propulsion Laboratory at Edwards AFB in California. He spent a successful career in the metals and petroleum chemicals industry in engineering and environmental health, retiring as Corporate Vice President.

LaTanya Patton (Missouri)  
Director At Large, National Alliance of State Prostate Cancer Coalitions  
LaTanya currently serves as the President and CEO of Missouri Prostate Cancer Alliance (MoPCA) which she co-founded in 2013. In addition to her professional work, she is the primary caregiver for her mother who is stricken with Alzheimer’s disease. LaTanya is a brain aneurysm survivor and supports the University of... continued on next page
LaTanya Patton continued

Kansas Health System Brain Aneurysm support group.

Prior to Missouri Prostate Cancer Alliance, she worked for Blue Cross and Blue Shield of Kansas City; Heart to Heart International – assigned to the country of Haiti; served as President and CEO of a small minority agency; Vice-President of Community Relations of MAST Ambulance and worked in various capacities for the City of Kansas City Missouri for 16 years including the Health Department before leaving to furthering her professional career.

LaTanya’s community service activities include serving as an Ambassador for American Heart Association, The Mayor’s Commission on AIDS/HIV (TGA), Ivy Community Service and Education Foundation, Swope Ridge Geriatric Center Board of Directors. She serves on the Board of Directors of NASPCC - Director at Large. LaTanya has been an active member of Alpha Kappa Alpha Sorority Incorporated for 34 years and is the immediate past President her chapter.

LaTanya has earned a Bachelor of Science in Business Administration from Lincoln University, Jefferson City, Missouri and is pursuing a Master in Business Administration from the University of Phoenix with an emphasis in organizational development and non-profit leadership. In addition, LaTanya considers herself a consistent leaner and is completing a teaching certification program at Western Bible College in Christian Education.

She has been a devoted member of her church in Kansas City, Missouri for the past 35 years where she serves as Culinary Leader, Youth Director and Vacation Bible School Director. She wants you to know that she is a “CHILD OF THE KING.” She has received numerous awards and recognitions.

LaTanya is happily married to Frederick Patton and has two beautiful daughters, Lauren Patton, and Logan Patton. In her spare time, she enjoys reading, shopping, participating community service activities with the sorority, volunteering and traveling with her family.

Thomas Kirk
Invited Member, National Alliance of State Prostate Cancer Coalitions

Tom Kirk has been heavily involved in Patient Advocacy Non-Profit Organizations. He currently serves as the Vice-President of the California Prostate Cancer Coalition (CPCC), which is “A Proud Participant in the National Alliance of State Prostate Cancer Coalitions” (NASPCC). Tom is also an Invited Member of the NASPCC Executive Committee.

Tom developed the Strategic Plan for NASPCC in 2017 and as Chair of NASPCC’s Steering Committee, he monitors the Plan’s implementation with the NASPCC Committees that were created to move it forward. Tom also serves on the NASPCC Advocacy and Public Policy Committee which, following NASPCC’s 2018 Bone Health Access Initiative (BHI), and the October Bone Health Access Roundtable, prioritized “Step Therapy and Access” as an issue.

In prostate cancer, Tom served as the President and CEO of Us TOO International in suburban Chicago for over 10 years, before moving to California in 2016. He currently works as a Co-Founder of Informed Health Consulting (IHC).

Additionally, Tom worked for over 12 years at the National Alzheimer’s Association headquartered in Chicago. He worked on the Senior Management Team where he was the Vice President of Patient, Family and Education Services. He has also assisted other Residential Care Providers (Mather Life Ways and Belmont Village) develop their Dementia Care Services, and he worked as the Vice President of Operations for Life Care Centers of America’s Garden Terrace Associates managing their specialized Dementia-Specific Long-Term Care Centers and Dementia Care Units. Tom holds an MSSW Degree in Planning and Administration from the University of Wisconsin-Madison.

BOARD OF DIRECTORS 2018-2019

Mary Anderson
North Carolina
Ira Baxter
Tennessee
Alvin Chin
Virginia
Judy Green
Massachusetts
Dave Hulbert
Minnesota
Paul Kradel
West Virginia
Robin Leach
Texas
Harold Pharoah
Nebraska
Gabe Rosko
New Jersey
Otto Sankey
Arizona
Renee Savickas
Colorado
James West (*deceased)
Florida
Michael Zaragoza
Delaware
"Reaching Thousands of Prostate Cancer Patients and their Families Across the U.S. Since 2004”

MISSION STATEMENT
NASPCC is a nation-wide organization, comprised of state prostate cancer coalitions, dedicated to saving men’s lives and enhancing the quality of life of prostate cancer patents and their families, through awareness and education and the development of a public policy network.

LEADERSHIP
NASPCC has an elected Board of Directors made up of State Representatives, which meets four times a year; and a Standing Executive Committee which meets monthly, composed of the four Officers, an elected Director-at-Large and an Invited Member. Eight Advisory Committees were formed in November 2017 to help accomplish the goals of the Strategic Plan adopted in July 2017. In September 2018, the Executive Committee created a Standing Committee, chaired by Tom Kirk, to monitor and strengthen the progress of these eight Advisory Committees:

- Advocacy and Public Policy, 2018-19 Chair: Alvin Chin/Donald Lynam
- Annual Meeting Committee, 2018-19 Chair: Merel Grey Nissenberg
- Budget Committee, 2018-19 Chair: Donald Lynam
- Communications Committee, 2018-19 Chair: Renee Savickas
- Education and Awareness Committee, 2018-19 Chair: Fran Franklin
- Fundraising Committee, 2018-19 Chair: Merel Grey Nissenberg
- Medical Advisory Committee: 2018-19 Chair: Michael Zaragoza, MD
- State Coalition Development Committee, 2018-19 Chair: Ira Baxter

REACHING PATIENTS AND THEIR FAMILIES
NASPCC supports the development of state prostate cancer organizations, each of which is comprised of patient networks and support groups. NASPCC through its Annual Meeting, webinars and other activities shares prostate cancer information with all of its participating state prostate cancer organizations, and this material is then disseminated to patients and their families, demonstrating the breadth and depth of our reach. NASPCC also helps equip patients and their families to actively engage in the prostate cancer cause.

THE NASPCC ANNUAL MEETING
The Annual Meeting pulls together leaders in the rapidly developing field of prostate cancer – patients and families, researchers, practitioners, and people interested in the disease – who want to share, learn and lead. The patient community is unique and the contemporary overview in the Take Home Messages from the Annual Meeting allows them to become empowered to do things locally. NASPCC creates support and a forum to enrich and rejuvenate these individuals and state organizations.
Dr. Paul Schellhammer received his undergraduate education at the University of Notre Dame and his medical school training and Cornell Medical College in New York City. His surgical and urologic training were taken at the University Hospital of Cleveland in Cleveland, Ohio and the Medical College of Virginia, Richmond, Virginia. This was followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. Subsequently he joined the practice of Devine Poutasse Fiveash Urology and became a faculty member of Eastern Virginia Medical School, where he eventually achieved the rank of Professor and then also served as Chairman of the Department of Urology and Program Director of the Resident Training Program.

Dr. Schellhammer has made many contributions to the field of urologic oncology and published widely in that discipline, especially in prostate cancer. He serves on several editorial boards, and has served as a trustee of the American Board of Urology as its President. He has also served as President of the Society of Urologic Oncology, as President of his Mid-Atlantic Section of the American Urologic Association, as a member of the Board of Directors of the American Urologic Association, and President of the American Urologic Association 2007-2008.

Mention Paul Schellhammer’s name to physicians, patients and others involved in prostate cancer and – truly uniformly - everyone has something glowing to say about him. Dr. Schellhammer’s unique position as both a urologist treating patients with prostate cancer, and a prostate cancer patient himself, gives him the benefit of approaching care of the body and person in the most dedicated, appropriate way.

The New Paul F. Schellhammer Cancer Center (“Groundbreaking Urological Oncology Treatment and Research”) was dedicated to him in 2012. It is “a urologic oncology center emphasizing innovative, cutting-edge cancer care. With a commitment to research, a partnership with the urology department at Eastern Virginia Medical School, and international collaboration, patients benefit from a unique approach to urologic cancer care.” What an honor!

Thank you, Paul F. Schellhammer, for everything you do, and everything you have done, for patients and their families!
Phillip Buck Olsen graduated from Wesleyan University, Middletown, CT with an AB in English in 1953. Drafted for duty during the Korean War, he joined the USAF as an Aviation Cadet in 1953, and graduated from single-engine jet flight training, Class of 55-E as an officer and pilot. He graduated from UCLA with a MS Journalism, became a public relations representative for Western Airlines, joined the Peace Corps as a volunteer, served in the Philippines as volunteer leader and regional director for Mindanao/Sulu, and became Philippines Desk Officer in Peace Corps Washington headquarters.

Phil joined the University of Hawaii in 1967 as training director for Peace Corps programs, and accepted associate deanship and administrative directorship in 1971 for the U.H. College of Arts & Sciences. He retired from the University of Hawaii in 1985 and then accepted a position with Alexander & Baldwin, Inc. as corporate pilot in a newly established flight department that he helped organize.

In 1989, Phil’s FAA-designated medical examiner found an induration on his prostate during a routine flight medical examination. He was diagnosed with prostate cancer in 1993, initial GS of 6, subsequently re-evaluated by an expert pathologist at Stanford U. as GS 4+ 4 = 8, PSA -19.4, CS= C, or possibly D, T3, m-1, NX, followed by 7,000 rads External Beam Radiation, and subsequently treated with Androgen Deprivation Therapy (Lupron plus Eulexin) for many years, with Actonel & Xgeva to combat bone-density loss. Phil participated in two important clinical trials: First, in 2002, he was accepted into a University of Illinois at Chicago Phase I Clinical Trial of PSA/Peptide-Based Specific Active Immune Therapy in HLA-A2+ Patients with Prostate Cancer, applied in ten subcutaneous, vaccinations using a vaccine produced with Granulocyte-Macrophage Colony Stimulation Factor (GM-CSF), and achieved apparent immune remission, which continued for more than four years.

In 1999, Phil was named Hawaii Regional Director of Us TOO International, and in 2004 he became a founding member of the National Alliance of State Prostate Cancer Coalitions (NASPCC) Board of Directors. In 2006 he became founding President of the Hawaii Prostate Cancer Coalition, a federal and state tax-exempt 501 (c) (3), volunteer corporation dedicated to making prostate cancer a health priority in the Island State, and pressing for public awareness to enable early detection of the disease.

In 2017, Phil enrolled in the University of Hawaii Cancer Center Phase 1B Clinical Trial, Protocol Rosser 2015-4 WIRB #20152124, assessing sequencing of Atezolizumab, (anti-PD-L1, Tencentriq), and Sipleucel-T (Provenge). He resigned from the trial after ten months because of debilitating joint inflammations. Subsequently, his California-based prostate cancer specialist began treating him with Zytiga, causing his PSA to drop out of sight to 0.0.

Congratulations, prostate cancer warrior Phillip Buck Olsen! You deserve the newly-created James West Spirit Award!
Asha Das, MD
Chief Medical Officer,
Progenics Pharmaceuticals

Dr. Das is Chief Medical Officer of Progenics Pharmaceuticals. She has almost 15 years of experience with pharmaceutical organizations, including Genentech where she was responsible for leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to TECENTRIQ®. Previously, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center. She has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore, served as a clinical fellow in neuro-oncology at Massachusetts General Hospital, and completed her residency in neurology at New York Presbyterian Hospital/Weil Cornell Medical Center. Dr. Das obtained her medical degree from Weil Cornell Medical College and bachelor’s degree from Cornell University.

Leonard Gomella, MD, FACS
Professor, Thomas Jefferson University
Kimmel Cancer Center

Leonard G. Gomella, MD, FACS, is the Bernard W. Godwin, Jr., Professor of Prostate Cancer and Chairman of the Department of Urology at the Sidney Kimmel Medical College. He serves as Senior Director for Clinical Affairs for the NCI-designated Sidney Kimmel Cancer Center at Jefferson, Clinical Director of the SKCC Network, and Urology Chair for NRG (RTOG). He has given over 500 presentations, written over 400 papers, and edited dozens of chapters and monographs. Dr. Gomella has also authored and edited 63 editions of 17 different books for medical students, residents, and practicing physicians. His Recovering from Prostate Cancer was the

continued on next page

National Alliance of State Prostate Cancer Coalitions

15th Annual Meeting

Jeanney Aragon-Ching, MD, FACP
Clinical Program Director,
Inova Schar Cancer Institute

Jeanney B. Aragon-Ching, M.D., F.A.C.P. serves as the Clinical Program Director of Genitourinary Cancers at the Inova Schar Cancer Institute in Fairfax, Virginia, United States with a joint academic appointment as Associate Professor of Medicine at Virginia Commonwealth University. She completed internship and residency at the Albert Einstein Medical Center in Philadelphia, Pennsylvania where she served the final year as Chief Resident. She later completed a Medical Oncology Fellowship at the National Cancer Institute, National Institutes of Health, in Bethesda, Maryland, where she served as an Associate Investigator on varying trials involved with pharmacogenomics, and early drug discovery for prostate cancer. Dr. Aragon-Ching later moved to the George Washington University Medical Center in 2008 and was promoted to the rank of Associate Professor of Medicine in 2014. Her early research work focused on the use of angiogenesis inhibitors, bone-targeted agents, clinical trial design and drug development. She has served in varying capacities as a peer reviewer, editorial board member and expert panel for highly acclaimed journals and congressionally directed research program grants. She was awarded the Elaine Snyder Cancer Research Award for exploring the role of circulating tumor cells in biochemical recurrence of prostate cancer. Dr. Aragon-Ching has chaired national meetings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and has given esteemed presentations at the Society of Urologic Oncology, Best of ASCO, AUA Plenary, GW Best Practices Course, and the ASCO Annual Meeting. She was recruited to Inova Schar Cancer Institute in 2015 to spearhead the GU Oncology program and bring together multidisciplinary expertise and advancement of research, clinical trial development, and personalized clinical care of patients with GU cancers. She has since served in the ASCO GU Program Planning Committee from 2017-2019 and served in the ASCO Cancer Education Committee for GU cancers.

Gregory Gagnon, MD
Radiation Oncologist, Frederick Regional Health System

Dr. Gregory Gagnon is a Radiation Oncologist specializing in Cyberknife at Frederick Regional Hospital. Dr. Gregory Gagnon also is an Associate Professor in the Department of Radiation Medicine at Georgetown University. He received his medical degree from the University of Virginia School of Medicine and completed his residency at Georgetown University. Dr. Gregory Gagnon has been in practice for more than 20 years and also specializes in Stereotactic Radiosurgery, Pd-103/I-125 Interstitial Prostate Implantation, and High Dose-Rate (HDR) Ir-192 Interstitial Prostate Implantation.

Joseph Germ ino, MD, PhD
Vice President, Bayer Pharmaceuticals

Dr. Joseph Germ ino is the Vice President at Bayer Pharmaceuticals. He received his medical degree from Duke University School of Medicine and completed his Postdoctoral Fellowship at Yale University School of Medicine. Dr. Germ ino joined Bayer as an Associate Director in 2005. In 2009 Dr. Germ ino became the Vice President of Bayer Pharmaceuticals.

Bill Gooren, MSW, OSW-C, LCSW-R
Clinical Program Director, CancerCare

Bill Gooren is the Director of Clinical Programs at CancerCare. Prior to his work at CancerCare, William was the Director of Mental Health for the AIDS Healthcare Foundation in Los Angeles, and, in 1994, opened the first Gilda’s Club in New York City. He is the co-author of the chapter “Unique Issues Confronting Gay, Lesbian, and Bisexual Individuals Diagnosed with Cancer” for the Oxford University Press Handbook of Oncology Social Work and the author of the chapter “Social Work, HIV Disease, and Palliative Care” for the Oxford Textbook of Palliative Social Work. He currently moderates CancerCare’s Online Support Group in Prostate Cancer that is co-sponsored by NASPCC.

Dr. Joseph Germ ino is the Vice President at Bayer Pharmaceuticals. He received his medical degree from Duke University School of Medicine and completed his Postdoctoral Fellowship at Yale University School of Medicine. Dr. Germ ino joined Bayer as an Associate Director in 2005. In 2009 Dr. Germ ino became the Vice President of Bayer Pharmaceuticals.
Leonard Gomella continued
first book published for the general public specifically on the topic of prostate cancer. He is also Editor-in-Chief of the Canadian Journal of Urology. In 2007, Men’s Health Magazine listed Dr. Gomella as one of the 20 top urologists in the US, and he received national recognition in Newsweek in 2015. He is the former President of the Mid-Atlantic Section of the AUA and the Society of Urologic Oncology. He has been elected to the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons. In 2015 he received a “Distinguished Contribution Award” from the AUA, and Jefferson honored him with the “Jefferson Achievement Award in Medicine.”

James Gulley, MD, PhD, FACP
NIH Lead Prostate Cancer Researcher
Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program, he completed a dissertation on tumor immunology. He completed his residency in Internal Medicine at Emory University in 1998, followed by a Medical Oncology fellowship at the National Cancer Institute (NCI).

Dr. Gulley serves within the Center for Cancer Research (CCR) of the National Cancer Institute as Chief of the Genitourinary Malignancies Branch (GMB), the Director of the Medical Oncology Service (CCR), and also Head of the Immunotherapy Section within the GMB. He has been instrumental in the clinical development a number of therapeutic cancer vaccines. In addition, he was the coordinating PI of an international trial of avelumab that led to regulatory approval and serves as the coordinating PI of the international M7824 bifunctional agent targeting PDL1 and TGF-beta.

Dr. Gulley serves on many national and NIH boards and committees. He has been an investigator on more than 120 clinical trials, authored more than 250 scientific papers or chapters, serves on a number of editorial boards and has made hundreds of presentations at national / international meetings. This will be his third appearance for NASPCC’s Annual Meetings.

Vincent Laudone, MD
Chief of Surgery,
Josie Robertson Surgery Center (JRSC) at Memorial Sloan Kettering Cancer Center
Dr. Vincent Laudone is Chief of Surgery for the Josie Robertson Surgery Center (JRSC) at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Laudone joined the Urology Service in the Department of Surgery at MSKCC in 2008 and was charged with building the robotic surgical program for the Department. Prior to that he completed a fellowship in Urologic Oncology at MSKCC in 1986 and practiced for twenty years as a founding member of the Connecticut Surgical Group working at Hartford Hospital and the University of Connecticut. In his current role as Chief of Surgery for the JRSC, Dr. Laudone is part of the team that helped design, open, and now run MSKCC’s new unique short-stay ambulatory cancer surgery facility. His clinical focus is on the treatment of men with prostate cancer and his research on improving the effectiveness, efficiency, and quality of care delivered in an ambulatory surgical environment.

Mark Markowski, MD, PhD
Assistant Professor, John Hopkins University
Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an instructor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and see patients in the genitourinary clinics of both hospitals. He is board-certified in medical oncology and internal medicine by the American Board of Internal Medicine. Dr. Markowski treats numerous types of cancers, with a specialty in prostate cancer.

Dr. Markowski earned his medical degree and PhD in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski is a board member and secretary for the Genito-Urinary Multidisciplinary D.C. Regional Oncology Project (GUMDROP).

Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, and anti-inflammatory agents and cancer incidence. Dr. Markowski is currently conducting research with funding from a Postdoctoral Training Award from the Department of Defense’s Prostate Cancer Research Program, and a Young Investigator Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients and credentialing these treatments for advancement to clinical trials.

Adam Metwalli, MD
Professor, Howard University Hospital
Adam R. Metwalli, MD, is a Professor at the Howard University College of Medicine and Chief of Urology in the Department of Surgery at Howard University Hospital. Dr. Metwalli is a urologic oncologist trained in robotic surgery and specializing in cancers of the kidney, prostate, bladder, penis, and testis. He joined the Division of Urology at Howard University Hospital in the Spring of 2018 after nearly 7 years as the primary kidney cancer surgeon at the Urologic Oncology Branch (UOB) of the National Cancer Institute in the National Institutes of Health (NIH). Prior to joining the NIH, Dr. Metwalli spent 3 years in private practice as the only fellowship-trained urologic oncologist in a large urology group in Baltimore Maryland. During his time with the Urologic Oncology Branch, Dr. Metwalli has expanded the use of robotic surgery in the treatment for multifocal kidney cancer as well as for repeat and salvage renal surgery. As a result, Dr. Metwalli developed a national and international reputation and has been asked to speak on the surgical management of kidney cancer across the country and around the world.

Dr. Metwalli has published over 50 research manuscripts in peer-reviewed journals and has contributed to dozens more as a participant in the Cancer Genome Atlas Research Network. Dr. Metwalli is actively involved in clinical trials research; he was the Principal Investigator for a Phase II clinical trial evaluating a novel small molecule radiotracer in patients with clear cell kidney cancer and has been an associate investigator on several other trials.

Prior to joining the UOB, Dr. Metwalli earned the Ruth L. Kirschstein National Research Service Award Research Training Grant from 2005 to 2006 and was awarded the AUA/Praecis...
Adam Metwalli continued

Pharmaceuticals Gerald P. Murphy Scholar Award and the Pfizer Scholar in Urology. Dr. Metwalli earned a medical degree from Wake Forest University School of Medicine prior to completing a surgical internship at the University of Louisville Hospital and a urology residency at the Oklahoma University Health Sciences Center. He then completed fellowships in urologic oncology at the University of Texas MD Anderson Cancer Center and at the Urologic Oncology Branch of the National Cancer Institute. Dr. Metwalli is an active member of the Society of Urologic Oncology, the American Urological Association and a board member for the Genitourinary Malignancies DC Regional Oncology Project (GUMDROP) and has previously served as member of the Medical Advisory Board for the National Kidney Foundation.

Judd Moul, MD, FACS
Professor, Duke University

Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients. Dr. Moul has received grants from the National Institutes of Health, U.S. Department of Defense, Veterans Affairs and CaPCURE Foundation, and managed a cumulative $50 million in grants from the U.S. Army Medical Research and Materiel Command for the Department of Defense Center for Prostate Disease Research.

Dr. Moul serves on the editorial boards of American Journal of Men’s Health, Urology and Prostate Cancer and Prostatic Diseases. He serves on the Executive Committee for the American Joint Commission for Cancer (AJCC). Dr. Moul has published over 600 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has been a visiting professor and invited guest lecturer at universities and national symposia, in addition to appearances on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General of the US Army, and the Castle Connolly National Physician of the Year award in 2009.

Ashley Ross, MD, PhD
Urologist, Texas Urology Specialists

Dr. Ross is a urologist and physician-scientist with a clinical focus on prostate cancer. He is part of Texas Oncology and Texas Urology Specialists, serves as the Executive Medical Director of the Mary Crowley Cancer Research Center in Dallas, and is an associate chair for the US Oncology Research genito-urinary committee. Previously, Dr. Ross directed the Brady Urological Prostate Cancer Program of the Johns Hopkins School of Medicine. Dr. Ross has led research efforts in basic science, translational, and clinical areas of prostate cancer research and has published over 100 peer-reviewed original articles regarding prostate cancer. He has participated in several of NASPCC’s Annual Meetings.

Philip Saylor, MD
Medical Oncologist, Massachusetts General Hospital Cancer Center

Philip Saylor MD is a genitourinary medical oncologist and clinical/translational investigator at the Massachusetts General Hospital Cancer Center. His research is focused on prostate cancer with an emphasis on survivorship and the metabolic side effects of systemic treatment strategies. He earned his MD from the University of Pittsburgh School of Medicine, then completed his internal medicine residency at the University of California San Diego. His fellowship training in medical oncology was at Dana Farber Cancer Institute and MGH.

Paul Schellhammer, MD, FACS
Professor, Urology of Virginia

Dr. Paul Schellhammer received his undergraduate education at the University of Notre Dame and his medical school training and Cornell Medical College in New York City. His surgical and urologic training were taken at the University Hospital of Cleveland in Cleveland, Ohio and the Medical College of Virginia, Richmond, Virginia. This was followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. Subsequently he joined the practice of Devine Poutasse Fiveash Urology and became a faculty member of Eastern Virginia Medical School where he eventually achieved the rank of Professor and then also served as Chairman of the Department of Urology and Program Director of the Resident Training Program.

Dr. Schellhammer has made many contributions to the field of urologic oncology and published widely in that discipline, especially in prostate cancer. He serves on several editorial boards, and has served as a trustee of the American Board of Urology as its President. He has also served as President of the Society of Urologic Oncology, as President of his Mid-Atlantic Section of the American Urologic Association, as a member of the Board of Directors of the American Urologic Association, and President of the American Urologic Association 2007-2008.

It is the pleasure of NASPCC to present Dr. Schellhammer with our Special Award at our 15th Annual Meeting & Gala on October 19, 2019! He will receive the Award at the Saturday evening Gala that begins at 6:30 p.m. in the Paris Room at the Hotel Monaco in Washington, DC.

Joseph Scherger, MD, PhD
Vice President, Eisenhower Health Center

Joseph E. Scherger, MD, M.P.H., a long-time Board Member of the California Prostate Cancer Coalition, is a family physician with Primary Care 365 at the Eisenhower Health Center in La Quinta, CA. He is also a core faculty with the Eisenhower Health Family Medicine Residency Program. Dr. Scherger is Clinical Professor of Family Medicine at the Keck School of Medicine at the University of Southern California (USC). Dr. Scherger is a leader in transforming office practice and has special interests in nutrition and using lifestyle change to reverse disease. He is the author of two books, 40 Years in Family Medicine (2014) and Lean and Fit: A Doctor’s Journey to Healthy Nutrition and Greater Wellness (Third Edition, 2019). Dr. Scherger is a Senior Fellow with the Estes Park Institute.

Dr. Scherger graduated from the University of Dayton in 1971, summa cum laude. He graduated from the UCLA School of...
Joseph Scherger continued

Medicine in 1975, and was elected to Alpha Omega Alpha. He completed a Family Medicine Residency and a Masters in Public Health at the University of Washington in 1978. From 1978-80, he served in the National Health Service Corps in Dixon, California, as a migrant health physician. From 1992-1996, he was Vice President for Family Practice and Primary Care Education at Sharp HealthCare in San Diego. From 1996-2001, he was the Chair of the Department of Family Medicine and the Associate Dean for Primary Care at the University of California Irvine. From 2001-2003, Dr. Scherger served as founding dean of the Florida State University College of Medicine.

Dr. Scherger has received numerous awards, including being recognized as a “Top Doc” in San Diego for six consecutive years, 2004-2009. In 1992, Dr. Scherger was elected to the National Academy of Medicine (Institute of Medicine) of the National Academy of Sciences. He received the Lynn and Joan Carmichael Recognition Award from the Society of Teachers of Family Medicine in 2012. In 2016 Dr. Scherger received the Desert Health Integrative Practitioner Wellness Award. He was the 2017 President of the Riverside County Medical Association.

Dr. Scherger served on the Board of Directors of the American Academy of Family Physicians and the American Board of Family Medicine. Dr. Scherger currently serves on the editorial board of Medical Economics and was an Assistant Editor of Family Medicine from 2010-2017. He has authored more than 500 medical publications and has given over 1100 invited presentations.

William “Jeff” Skinner, MD
Chief Military Medical Operations at Uniformed Services,
University of the Health Sciences

Dr. Skinner received his BS in Biology at the United States Air Force Academy, and his MD at the University of Virginia School of Medicine. He then completed his Residency in Radiation Oncology through the Radiology Oncology Residency Program at Albert Einstein College of Medicine. Dr. Skinner is currently a Radiation Oncologist at Walter Reed National Military Medical Center; Chief, Military Medical Operations at the Uniformed Services University of the Health Sciences; and principal investigator at the Armed Forces Radiobiology Research Institute. Until last month Dr. Skinner was also Program Director, Radiation Oncology Residency Program for the National Capital Consortium.

Daniel Song, MD
Associate Professor, Johns Hopkins Medicine

Dr. Daniel Song is Associate Professor, Director of Genitourinary Radiation Oncology, Co-Director of the Prostate Cancer Multi-Disciplinary Clinic, and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins. His areas of research include the development and refinement of new imaging methods to improve radiation targeting, as well as the development of innovative means of reducing potential side effects of radiation treatment. His work is supported by funding from the National Cancer Institute as well as non-profit research grants.

He is a reviewer and examiner for the American Board of Radiology, and he serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on low-dose-rate brachytherapy, stereotactic body radiation therapy, and image-guided robotic brachytherapy.

Anson Tharayanil
Medical Science Liaison, Genomic Health

Anson Tharayanil graduated from the University of California, Davis with a degree in Biological Sciences. With over a decade of experience in the biotechnology space, he has helped bring several multigene tests for breast, colon, and prostate cancer into clinical use. His passion is in educating both physicians and patients on the use and value of genomic tests to improve patient care.

Mark Vieth
Senior Vice President, CRD Associates

Mark D. Vieth, Senior Vice President, joined the firm in 2002 and manages a diverse portfolio of clients in several practice areas, including public health and medical research. Mark currently serves as the coordinator for several national coalitions, including the Defense Health Research Consortium. He has specialized in bringing diverse associations, foundations, institutions of higher education and other stakeholders together to advocate for common objectives. He has helped clients secure federal funding, build new partnerships with federal agencies and mobilize grassroots to advocate for legislation pending in Congress. He also has developed a niche in helping clients who have never interacted with Congress or federal agencies launch sophisticated and focused federal government relations strategies.

Prior to joining CRD Associates, Mark served for 14 years as a professional staff member in the House of Representatives. As Chief of Staff for Congressman Robert A. Borski (D-PA), Mark worked extensively on legislative issues and projects of importance to one of the nation’s major medical research clusters in Philadelphia. Mark is also past President and current Treasurer of the Pennsylvania Society of Washington, D.C. He earned his B.A. in international relations from Syracuse University.

Krishnan Venkatesan, MD
Director of Urologic Reconstruction,
Washington Hospital Center

A native of Detroit, Krishnan completed his undergraduate studies at Columbia University in the City of New York before returning home for medical school at Wayne State University. He stayed on at Wayne State for his residency in Urology which he completed in 2010. He then undertook a fellowship in Genitourinary Reconstruction at the Institute of Urology at University College London and went on to Pune, India to pursue further training in complex urethral reconstruction at the Kulkarni EndoSurgery Institute.

Krishnan then moved to Washington, DC to become the Director of Urologic Reconstruction at MedStar Washington Hospital Center, a 900-bed urban tertiary care and trauma center. He is an Associate Professor in the Georgetown University Department of Urology and participates actively in resident training. Over his seven years in Washington, he has developed the Reconstructive Unit into a referral center for complex genitourinary reconstruction and prosthetics throughout the Mid-Atlantic Region. He has had his work presented at the regional, national and international level, and has co-authored a number of publications in the urologic reconstruction subspecialty.
NASPCC would like to thank the following sponsors for their support:

- Dendreon
- Bayer
- Pfizer
- Genomic Health
- Progenics Pharmaceuticals
- Boston Scientific
- Sanofi Genzyme
- Amgen
- Merck
- Janssen Oncology
- Accuray
- Janssen
- Genentech
- Decipher Biosciences